Healthcare Services

A significant industry trend in the Vasoactive Intestinal Peptide Tumor Market includes the Advancements In Long-Acting Injectables Product Driving Patient Treatment Outcomes

April 7, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Vasoactive Intestinal Peptide Tumor Market At The End Of The 2026–2030 Forecast Period?

The market size for vasoactive intestinal peptide tumors has experienced substantial growth in recent years. It is anticipated to expand from $1.61 billion in 2025 to $1.7 billion by 2026, achieving a compound annual growth rate (CAGR) of 6.2%. This historical expansion can be attributed to several factors, including improved detection of neuroendocrine tumors, the increased availability of specialized oncology centers, the growing application of imaging-based diagnostics, the early adoption of somatostatin analog therapies, and advancements in pancreatic surgery techniques.

The vasoactive intestinal peptide tumor market size is set to experience significant expansion over the next few years. It is projected to reach $2.15 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.0%. This anticipated growth during the forecast period is driven by factors such as increasing research investments in rare cancers, the accelerated development of novel targeted drugs, wider adoption of precision medicine approaches, the expansion of specialized cancer care infrastructure, and increasing awareness of rare endocrine disorders. Key trends expected in the forecast period encompass the increasing adoption of targeted therapy approaches, the rising use of advanced imaging for early diagnosis, a growing focus on personalized treatment protocols, the expansion of minimally invasive surgical techniques, and the enhanced integration of multidisciplinary care models.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23561&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Vasoactive Intestinal Peptide Tumor Market?

The expansion of targeted therapy is projected to fuel the growth of the vasoactive intestinal peptide tumor market moving forward. These treatments specifically aim at particular molecules or pathways linked to disease development, especially in cancer, enabling the selective destruction of abnormal cells while largely sparing healthy ones. The advancement of targeted therapies is propelled by precision medicine, which improves effectiveness by concentrating on specific genetic mutations and reducing adverse reactions. For VIP tumors, targeted therapies function by obstructing crucial pathways that promote tumor expansion and hormone secretion. This intervention helps to lower VIP levels, alleviating symptoms like severe diarrhea and decelerating disease progression. An illustrative example is seen in July 2024, when the American Society of Gene and Cell Therapy (ASGCT), a professional membership organization based in the US, reported that 76 gene therapy trials commenced in the second quarter of 2024, representing a 25 % rise from the preceding quarter. Consequently, the increasing prevalence of targeted therapy is a key factor driving the expansion of the vasoactive intestinal peptide tumor market.

What Segment Types Make Up The Vasoactive Intestinal Peptide Tumor Market?

The vasoactive intestinal peptide tumor market covered in this report is segmented –

1) By Treatment: Surgical Intervention, Radiotherapy, Chemotherapy, Targeted Therapy

2) By Diagnosis: Imaging Techniques, Biopsy, Endoscopic Ultrasound

3) By Therapeutic Approach: Palliative Care, Curative Treatment, Adjuvant Treatment

4) By End-User: Hospitals, Cancer Specialty Clinics, Diagnostic Laboratories

Subsegments:

1) By Surgical Intervention: Tumor Resection, Debulking Surgery, Minimally Invasive Surgery

2) By Radiotherapy: External Beam Radiation Therapy (EBRT), Stereotactic Body Radiation Therapy (SBRT), Proton Therapy

3) By Chemotherapy: Cytotoxic Chemotherapy, Combination Chemotherapy, Adjuvant And Neoadjuvant Chemotherapy

4) By Targeted Therapy: Somatostatin Analog Therapy, Tyrosine Kinase Inhibitors (TKIs), Monoclonal Antibodies

How Are Trends Shaping The Direction Of The Vasoactive Intestinal Peptide Tumor Market?

Major companies within the vasoactive intestinal peptide tumor market are concentrating on developing advanced products, such as long-acting injectable suspensions, to boost treatment effectiveness, improve patient compliance, and offer sustained symptom relief. These long-acting injectable suspensions are medications formulated to release their active ingredients gradually over an extended duration, thereby reducing the need for frequent dosing. For instance, in October 2024, Teva Pharmaceutical Industries Ltd., a US-based pharmaceutical company, introduced the first and only generic version of Sandostatin LAR Depot (octreotide acetate for injectable suspension) in the U.S. This medication is utilized for long-term maintenance therapy in acromegaly patients who showed an inadequate response to surgery or radiotherapy. It also addresses severe diarrhea and flushing associated with metastatic carcinoid tumors and VIP-secreting tumors. This launch emphasizes Teva’s expertise in complex generics and supports its aim of maintaining a strong presence in the generic pharmaceuticals market.

Who Are The Key Players Driving Competition In The Vasoactive Intestinal Peptide Tumor Market?

Major companies operating in the vasoactive intestinal peptide tumor market are Pfizer Inc., Novartis AG, Mayo Clinic, Mount Sinai Hospital, Cleveland Clinic Laboratories, Penn Medicine, Stanford Health Care, UCSF Health, ARUP Laboratories, Dr. Lal PathLabs, Cancer Research UK, Medicover Hospitals, Ganesh Diagnostic, Ipsen Pharma SA, F Hoffmann-La Roche Ltd, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Merck & Co

Read the full vasoactive intestinal peptide tumor market report here:

https://www.thebusinessresearchcompany.com/report/vasoactive-intestinal-peptide-tumor-global-market-report

Which Regions Are Projected To Dominate The Vasoactive Intestinal Peptide Tumor Market In The Coming Years?

North America was the largest region in the vasoactive intestinal peptide tumor market in 2025. The regions covered in the vasoactive intestinal peptide tumor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Vasoactive Intestinal Peptide Tumor Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23561&type=smp

Browse Through More Reports Similar to the Global Vasoactive Intestinal Peptide Tumor Market 2026, By The Business Research Company

Glucagon Like Peptide 1 Global Market Report

https://www.thebusinessresearchcompany.com/report/glucagon-like-peptide-1-global-market-report

Peptide Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Gastrointestinal Stromal Tumor Global Market Report

https://www.thebusinessresearchcompany.com/report/gastrointestinal-stromal-tumor-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795